Trials / Completed
CompletedNCT00480467
Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SAM-315 in Healthy Japanese Males
Ascending Single Dose Study of the Safety, Tolerability, Pharmacokinetics (PK), and Pharmacodynamics (PD) of SAM-315 Administered Orally to Healthy Japanese Male Subjects
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 32 (planned)
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer · Industry
- Sex
- Male
- Age
- 20 Years – 45 Years
- Healthy volunteers
- Accepted
Summary
To assess the safety and tolerability of ascending single oral doses of SAM-315, an investigational drug, in healthy Japanese male subjects.To obtain preliminary pharmacokinetic (PK) and pharmacodynamic (PD) profiles of SAM-315 in healthy Japanese male subjects.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | SAM-315 |
Timeline
- Start date
- 2006-09-01
- Completion
- 2007-08-01
- First posted
- 2007-05-31
- Last updated
- 2007-12-05
Locations
1 site across 1 country: Japan
Source: ClinicalTrials.gov record NCT00480467. Inclusion in this directory is not an endorsement.